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Abstract 
Purpose: To develop a chitosan microsphere carrier system of bupivacaine for buccal administration. 
Methods: Chitosan microspheres loaded with bupivacaine were prepared by emulsification technique 
based on glutaraldehyde cross-linking and drug-loaded chitosan microsphere were coated with poly-
glycolic acid (PGA) film The formulated microspheres were characterized by x-ray diffraction (XRD), 
differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and in vitro release was 
performed in pH 7.4 phosphate buffer both in the presence and in absence of lysozyme. 
Results: Encapsulation yield was 83.1 %. SEM studies indicate that the microspheres were spherical 
and had a relatively smooth surface. XRD and DSC data indicate that there was no interaction between 
the drug and polymer. In vitro results show that in the presence of lysozyme, 39 % of the drug was 
released from the microspheres after 4.5 days while maximum drug release (42.5 %) was achieved on 
day 11. This compares with 31 % drug release on 4.5th day and 38 % on 11th day; maximum drug 
release occurred on day 11 in the absence of lysozyme.  
Conclusion: It is evident from this study that microspheres can potentially be used for controlled 
release of of bupivacaine for the management of dental pain in the buccal cavity. 
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Compared to general anesthesia with opioid-
based preoperative pain management regional 
anesthesia can provide benefits of superior pain 
control, improved patient satisfaction, decreased 
stress response to surgery reduced operative 
and post operative blood loss. Local anesthesia 
(LA) is valued for the ability to prevent membrane 
depolarization of nerve cells. LA prevents 
depolarization of nerve cells by binding to cell 
membrane sodium channels and inhibiting the 
passage of sodium ions.  
 
Bupivacaine has been widely used for local or 
regional anesthesia after surgery because of its 
rapid onset and relatively long-lasting anesthetic 
effect as compared to other commonly used LA 
[1]. Liposphere formulation of bupivacaine and 
lidocaine were previously evaluated as sustained 
release delivery system for LA [2]. Biostable 
systems such as hydro gels formed by different 
polymers and co-polymers have been used to 
release several drugs [3,4]. When the bio-
erodible system is used, one of the most 
important characteristics is its biocompatibility 
which means that the degradation products 
originated in the biodegradation process must be 
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metabolized by the organism system based on 
polylactide and polyglycolide and their copolymer 
[5]. Chitosan is the common name of a linear 
random copolymer of β-(1-4) linked –D-
glucosamine whose molecular structure 
comprises a linear backbone linked through 
glycosidic bonds. The basic amine groups of this 
polysaccharide are protonated and thus 
positively charged in the most physiological 
fluids. Chitosan is mostly hydrophilic and the 
proportion of acetylated monomers and their 
distribution in the chains has a critical effect on 
its solubility and conformation in aqueous media. 
These characteristics of chitosan have attracted 
many scientists working in biomedical area and 
particularly in drug delivery [6-9]  
 
Many structural factors such as concentration of 
polymeric matrix, pKa of the ionizable group, 
degree of ionization, cross linking, density, 
hydrophillicity influence the degree of swelling of 
polymers [10]. Since it can be biodegraded by 
enzyme action [11], the efficacy of conventional 
treatments of oral diseases i.e. Dental caries, 
fungal infections is often reduced by the limited 
retention of the applied formulation within the oral 
cavity [12-13]. The short residence time of the 
formulation at its intended site of action may 
result in reduced bioavailability [13].  
 
A large number of studies have documented the 
use of buccal delivery system for control release 
of drugs [13]. Chitosan microspheres as a 
formulation tool for the enhanced retention of a 
therapeutic entity within oral mucosa have been 
evaluated by in vitro test. One of the greatest 
challenges for applying pharmaceutical 
formulation based on chitosan in oral cavity is the 
presence of lysozyme; an enzyme widely 
distributed in different mammalian fluids such as 
saliva or vaginal fluid [14-15]. The literature has 
described the hydrolytic activity of lysozyme on 
chitosan [15]. The aim of this research was to 
develop an easy and simple sustainable oral 
drug delivery system using bupivacaine loaded 
glutaraldehyde cross-linked high molecular 







High molecular weight chitosan (HPC, mol wt 
{1.4 – 2.2} x 105) (Sigma Aldrich, Belgium.), 
Glutaraldehyde (sd fine chemicals, India), 
lysozyme (Sigma Aldrich, China), polyglycolic 
acid (PGA) (SD Fine Chemicals, India), Methanol 
(SD Fine Chemicals, India),   Bupivacaine (Fluka 
Analytical, Italy) were purchased. All other 
chemicals used were of analytical grades, and 
double-distilled water was used throughout the 
study.  
 
Preparation of bupivacaine–loaded chitosan 
beads   
 
Bupivacaine loaded chitosan beads were 
produced using the method reported elsewhere 
[15]. In brief, 2% w/v chitosan solution was 
prepared by dissolving medium weight chitosan 
in 2 %v/v acetic acid overnight at room 
temperature under constant stirring. Then the 
resulting solution was filtered to remove any 
physical impurities and 100 mg of bupivacaine 
was dissolved in 10 ml of the filtrate. The 
resulting solution was mixed with sodium 
hydroxide solution as a coagulant and methanol 
followed by syringe injection to form beads; 
glutaraldehyde (5 mol/L)  was added as a cross 
linking agent and incubated for 4 h at 25 oC to 
allow the beads to harden. Then beads were 
filtered and washed with excess solution of 
sodium bisulphate to remove excess of 
glutaraldehyde and finally beads were dried at 
room temperature.  
 
Preparation of bupivacaine-loaded films  
 
Bupivacaine/polyglycolic acid (PGA) films were 
prepared using the method reported elsewhere 
[15]. In brief, 50 mg of PGA (50 mg) was 
dissolved in 5ml of chloroform; 1 ml of resulting 
was spread on a glass plate. The resulting films 
were allowed to set at 27 oC for complete drying; 
100 mg of bupivacaine-loaded beads were 
dispersed on the film and subsequently 1 ml of 
PGA solution was added. Chloroform was 
completely evaporated and the resulting film was 
dried at 27 oC over calcium sulphate (CaSO4) for 
24 h and stored in a CaSO4 desiccator.  
 
Determination of drug content and 
encapsulation efficiency 
 
The concentration of drug in all the formulations 
was determined by UV-visible-NIR 
spectrophotometer 670 V (Jasco, USA). 
Bupivacaine–loaded chitosan beads (50 mg) 
were added to 57 ml of phosphate buffer (pH 7.5) 
containing 5 mg of lysozyme followed by stirring 
for 5 days at 37 oC. Assay of bupivacaine content 
was done using spectrophotometer at λmax of 263 
nm. Assay was performed in triplicate. The drug 
content (DC, %) and encapsulation efficiency 
(EE, %) were calculated as in Eqs 1 and 2.  
 
DC = (Md/Mm)100 ………………………… (1) 
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where Md is mass of drug in the microsphere 
and Mm is the mass of microsphere. 
 
EE = (DL/TL)100 ……………………….…… (2) 
 
where DL  is actual drug loading and TL  is 




Swelling of PGA blended with chitosan 
microsphere prepared using three different 
concentrations of cross linker as well as three 
different drug loadings were studied in water by 
measuring mass uptake at pH 7.4. Accordingly, 
the prepared networks in the form of beads were 
tested by placing 30mL buffer solution (pH 7.4) 
each and incubated at 600C. An appropriate time 
interval (30 min), beads were taken out and 
excess water was removed from the polymeric 
blends using filter paper and blends were 
weighed immediately using electronic weighing 
balance of accuracy 0.00001mg (Shimadzu, 
Japan). The swelling of microsphere was 
expressed as swelling ratio (S) using Eq 3.  
 
S = (W1-Wo)/Wo ………………………………. (3) 
 
where W1 is the weight of the sample at time t 
and W0 is the weight of dry sample. 
 
X-ray diffraction studies (XRD) studies 
 
X-ray diffraction (XRD) studies were carried to 
help to determine the crystallinity of the drug in 
the cross-linked network (Bucker Germany, 
CuKά radiation, Nickel filter). The XRD patterns 
of bupivacaine-loaded chitosan–PGA blend, 
blank bupivacaine loaded chitosan–PGA blend, 
and the pure drug were compared. 
 
Scanning electron microscopy (SEM) studies 
 
The surface and cross sectional morphologies of 
chitosan/citrate films were examined using high 
resolution scanning electron microscopy (HR-
SEM) (FEI Quanta FEG 200-high resolution 
scanning electron microscope). 
 
Differential scanning calorimetry (DSC) 
 
Pure bupivacaine and the drug-loaded 
microsphere were subjected to DSC (DSC Q 
1000V9.4 Build 287) analysis at a heating rate of 
10 °C/min over temperature range of 0 - 400 °C. 
 
In-vitro release study 
 
In vitro drug release studies were performed 
using a United States Pharmacopeia paddle-type 
dissolution apparatus (DA-1D, V Scientific, India)   
containing 100 ml of phosphate buffer (pH 7.4) 
as the dissolution medium. The film (~ 50 mg) 
was used for the study enclosed in a dialysis 
bag. Dissolution studies were performed at 37 ± 
2 oC at 500 rpm. Samples (5 ml) were withdrawn 
from the medium at various time intervals and 
the medium replenished immediately with the 
same volume of fresh dissolution medium to 
maintain sink conditions. The amount of 
dissolved drug in the sample taken was 
measured (after filtration through Whatman filter 
paper 41, pore size: 25µm) spectrophotome-
trically at λmax of 263 nm; a parallel experiment 
was conducted in which 5 mg of lysozyme was 
incorporated in the diffusion medium. Data 
obtained from in vitro release studies were fitted 
to Higuchi model to determine the mechanism of 
drug release from the chitosan microsphere. The 
tests were carried out in triplicate. 
 
Statistical analysis  
 
Statistical analysis was performed using Origin 
7.0 Scientific graphing and analysis software. All 
the tests were run in triplicate and the drug 
release data analyzed by one-way ANOVA with 




X-ray diffraction (XRD) 
 
XRD patterns (Fig 1) indicate that bupivacaine 
showed characteristic intense peaks at 10o and 
30o due to the crystalline nature of the drug. 
However, peaks for the plain drug were not seen 
for the drug-loaded microspheres due to 
encapsulation of the drug in the polymeric 
network, and same applied to the blank 
microspheres, thus indicating that the 
encapsulated drug became amorphous in nature. 
 
Fig 1:  XRD diffractogram of (A) pure drug (B) drug-
loaded chitosan matrix (C) blank microspheres 
 
Scanning electron microscopy  
 
The surface morphology of the drug-loaded 
microspheres, shown in Fig 2A, indicates that 
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they were fairly smooth and spherical in shape. 
Bupivacaine-loaded chitosan microspheres were 
embedded in PGA films but aggregated (Fig 2B). 
The results indicate good compatibility between 
the matrix and the drug. 
   
 
Fig. 2 (A) SEM of bupivacaine-loaded chitosan 
microspheres, (B) SEM of bupivacaine-loaded 
chitosan microsphere embedded in PGA                                              
 
Differential scanning calorimetry (DSC) 
 
DSC thermograms of chitosan, formulated 
microspheres and pure drug are shown in Figure 
3. The thermograms of chitosan showed a broad 
peak at 109 oC which was attributed to loss of 
water due to evaporation of absorbed water and 
no degradation, which would normally occur at 
280 oC, was observed for chitosan in the 
thermograms, [17-18]. Bupivacaine thermograms 
showed a broad beak at 255 oC which 
corresponds to its melting point which is usually 
in the range of 255 – 256 oC. This peak was 
absent in the thermograms for the drug-loaded 
chitosan microspheres, however, a peak 
appeared at 239 oC. This means that chitosan 
probably conjugated with bupivacaine to form a 
stable adduct. The conjugation between drug 
and chitosan was broken on heating and hence a 
new peak appeared at 239 oC.  
 
Drug content and encapsulation efficiency 
 
Drug content and encapsulation results are 
shown in Table 1. Three different loading 
concentrations of bupivacaine were assessed 
during cross-linking of the microspheres. The 
results show the increasing trends with 
increasing drug loading. Encapsulation efficiency 
of 63% was observed for plain chitosan 
microsphere but it ranges were from 67.4±0.6% 
to 83 ±0.8% for the other formulations. 
     
 
Fig 3:  DSC thermograms of (A) chitosan, (B) 
chitosan-drug loaded microspheres, and C) pure 
drug  
 
In vitro drug release 
 
The release profile of bupivacaine from the 
chitosan beads is shown in Fig 4. In vitro results 
show that in the presence of lysozyme, 39 % of 
the drug was released from the microspheres 
after 4.5 days while maximum drug release 
(42.5%) was achieved on day 11. This compares 
with 31 % drug release on day 4.5 in the 
absence of lysozyme and,38 % on day 11. 
Maximum drug release was achieved on day 11 
in the presence of lysozyme.  
 
On subjecting the drug release data to Higuchi 
model (Q = Kt½) in order to ascertain the drug 
release mechanism, a linear relationship was 





Ionized chitosan hydro gel and its swelling 
characteristics are dependent on its chemical 
structure and pH of the medium. The amount of 
crosslinking agent added to the polymeric matrix 
at equilibrium was based on the concentration of 
the functional group present in the polymeric  
        
    Table 1:  Encapsulation efficiency and swelling of the preparations 
 
Formulation core %PGA 
microphere 






CS-PGA-1       10 5 2.5 71.1±0.3                          327±0.1 
CS-PGA-2      10 5 5 67.4±0.6                          302±0.6 
CS-PGA-3     10 5 7.5 62.7±0.2                          291±0.3 
CS-PGA-4       20 5 5 78.8±0.1                          369±0.6      
CS-PGA-5     30 5 5 83.1 ±0.8                         393±0.2                                                                        
CS-PGA-6       10 5 5 64.2±0.2                          278±0.3 
     GA = glutaraldehyde;, *mean ± SD (n = 3) 
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Fig 4:  Cumulative release of (A) bupivacaine in the 
presence of lysozyme, and (B) in the absence of 
lysozyme 
 
network. The results of the present study show 
that the encapsulation efficiency was decreased 
with increased concentration of crosslinking 
agent glutaraldehyde from 71.1±0.3 (%) to 
62.7±0.2 and swelling from 327±0.1(%) to 
291±0.3 when the amount of PGA in 
microsphere (%) and drug (%) were same, but 
the encapsulation efficiency was increased with 
increased concentration of PGA from 64.2±0.2 
(%) to 83.1±0.8 and swelling from 369±0.5(%) to 
278±0.3, when the amount of glutaraldehyde (%) 
and drug (%) were same. The strength and water 
preservation efficiency of the hydro gel depends 
on the amount of crosslinking agent used 
because the chitosan molecules can be 
transformed into polymeric network structure by 
the addition of crosslinking agent and 
consequently, water molecules can be preserved 
in the network developed. If amount of cross 
linking is less, this would greatly affect the 
strength as well as the water preservation 
efficiency of the hydro gel towards the lower end. 
If excessive amount of crosslinking agent is 
used, this would result in a decrease in network 
volume for water preservation efficiency [19].  
 
The use of glutaraldehyde in the formulation of 
poorly soluble chitosan derivatives makes 
microspheres stronger [16]. Encapsulation 
efficiency increased with increasing PGA in the 
microspheres. This is due to the hydrophilic 
nature of PGA. Encapsulation efficiency 
decreased as the concentration of crosslinker 
increased. Such decreasing trend is due to 
increasing crosslink density because the 
microspheres became rigid, thereby reducing the 
free volume space within the polymer matrix and 
hence a reduction in encapsulation efficiency. 
 
The extent of crosslinking was dependent upon 
equilibrium swelling. For instance, equilibrium 
swelling ratio decreased from 327(%) to 291(%) 
leading to increasing crosslinking density and 
decreased pore volume of the formulation matrix. 
The XRD and DSC results obtained indicated 
that there were no interactions between 
bupivacaine, chitosan and other ingredients used 
in preparing the microsphere. This implies that 
the developed microspheres would be stable 
during the course of drug delivery. have 
disappeared in the drug loaded chitosan 
microspheres, it suggests the lowering of 
crystallinity in drug loaded matrix and results in 
more dispersion the polymeric matrix which 
indicates higher release in the system. Similar 
type of findings was reported when an 
amorphous drug, which is very difficult to 
measure at the detection limit of the crystal size, 
was dispersed molecularly in the polymer matrix 
and hence, no crystals were found in the drug 
loaded matrices [20].    
 
Chitosan microparticles may owe their promising 
mucoadhesive performance to their cationic 
nature. It has been suggested that within 
aqueous environment cationic materials display a 
mechanism of mucoadhesion in which not only 
hydrogen bonds, but also salt bridge effects 
involving the positively charged chitosan 
microparticles and the negatively charged 
mucous glycoproteins. The chitosan formulation 
in oral cavity releases more drug in the presence 
of lysozyme, an enzyme widely distributed in 
mammalian fluids such as saliva and vaginal fluid 
in cells like macrophages [14]. The hydrolytic 
activity of lysozyme on chitosan has 
demonstrated that the presence of lysozyme 
increases the total amount of drug released from 




Bupivacaine-loaded microspheres have been 
successfully prepared by emulsification 
technique, and the formulation seemed suitably 
designed for the control of dental pain in the 
buccal cavity, where lysozyme would act by 
facilitating bupivacaine release. Controlled 
release of bupivacaine in vitro up to 11 days can 
be achieved. Thus, high molecular weight 
chitosan microsphere embedded in PGA film 
may be suitable for in vivo delivery of 
bupivacaine in buccal cavity. Further research on 
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